Abstract
Evidence accumulated to date indicates that inhibition of the renin-angiotensin system with angiotensin receptor blockers (ARB) may prevent new-onset of diabetes. ARB is also used for the prevention of occurrence and progression of complications in diabetes and diabetic nephropathy. From the results of recent large-scale clinical studies, ARB is considered as a first choice drug in hypertensive patients with diabetes. In this review article, we focus on the effects of ARB on progression and prevention against diabetes as a metabolic-improving agent.
Keywords: Metabolism, prevention, nephropathy, retinopathy
Current Vascular Pharmacology
Title: Pleiotropic Effects of ARB in Diabetes Mellitus
Volume: 9 Issue: 2
Author(s): Shu-ichi Saitoh and Yasuchika Takeishi
Affiliation:
Keywords: Metabolism, prevention, nephropathy, retinopathy
Abstract: Evidence accumulated to date indicates that inhibition of the renin-angiotensin system with angiotensin receptor blockers (ARB) may prevent new-onset of diabetes. ARB is also used for the prevention of occurrence and progression of complications in diabetes and diabetic nephropathy. From the results of recent large-scale clinical studies, ARB is considered as a first choice drug in hypertensive patients with diabetes. In this review article, we focus on the effects of ARB on progression and prevention against diabetes as a metabolic-improving agent.
Export Options
About this article
Cite this article as:
Saitoh Shu-ichi and Takeishi Yasuchika, Pleiotropic Effects of ARB in Diabetes Mellitus, Current Vascular Pharmacology 2011; 9 (2) . https://dx.doi.org/10.2174/157016111794519363
DOI https://dx.doi.org/10.2174/157016111794519363 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Arterial Stiffness and Hypertension: A Review of Mechanism and Clinical Relevance
Current Hypertension Reviews VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design A Comprehensive Review on Exosomes and Microvesicles as Epigenetic Factors
Current Stem Cell Research & Therapy Common Variant in VEGFA and Response to Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration
Current Molecular Medicine Follicular Cysts: A Single Sign and Different Diseases. A View from Comparative Medicine
Current Pharmaceutical Design Editorial:Genomics and Epigenomics of Tumor and Aging Cells
Current Genomics Sustained Release of Verapamil Hydrochloride from Sodium Alginate Microcapsules
Current Drug Delivery Electrochemical Detection and Sensing of Reactive Oxygen Species
Current Organic Chemistry Impact of Antihypertensive Drug Use on Bone Mineral Density and Osteoporotic Fracture - From an Epidemiological Perspective
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Array-Comparative Genomic Hybridization Analysis of a Cohort of Saudi Patients with Epilepsy
CNS & Neurological Disorders - Drug Targets Hypoglycemic Hemiparesis Masquerading As Ischemic Stroke: When Guideline Fails
Current Drug Therapy “Tripping out” with the TRP Superfamily and TRPV1 for Novel Neuroprotection
Current Neurovascular Research Vasopressin Secretion Control: Central Neural Pathways, Neurotransmitters and Effects of Drugs
Current Pharmaceutical Design Recent Updates on the Systemic and Local Safety of Intranasal Steroids
Current Drug Metabolism Monoclonal Antibody-Based Targeted Therapy in Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Effects of a Long-Term Treatment with an Antioxidant Pyridoindole on Vascular Responsiveness in Diabetes-Induced Aging Rats
Current Aging Science Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry Toxicities by Herbal Medicines with Emphasis to Traditional Chinese Medicine
Current Drug Metabolism Determination of Interchangeability of Different Brands of Diclofenac Sodium Sustained Release Tablets in Healthy Subjects Using Pharmacokinetic End Points
Letters in Drug Design & Discovery Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology